These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12172412)

  • 1. Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity.
    Andrade RJ; Lucena MI; Fernández MC; Vega JL; García-Cortés M; Casado M; Guerrero-Sanchez E; Pulido-Fernandez F
    Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):887-90. PubMed ID: 12172412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Irbesartan induced acute hepatitis: one case].
    Péron JM; Robic MA; Bureau C; Vinel JP
    Gastroenterol Clin Biol; 2005; 29(6-7):747-8. PubMed ID: 16149188
    [No Abstract]   [Full Text] [Related]  

  • 3. Could irbesartan trigger autoimmune cholestatic hepatitis?
    Annicchiarico BE; Siciliano M
    Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):247-8. PubMed ID: 15674105
    [No Abstract]   [Full Text] [Related]  

  • 4. [Irbesartan-induced acute hepatitis].
    Foruny Olcina JR; Moreira Vicente VF; Gómez García M; Morell Hita JL
    Gastroenterol Hepatol; 2004 Feb; 27(2):71-2. PubMed ID: 14733885
    [No Abstract]   [Full Text] [Related]  

  • 5. Exanthematous reaction to irbesartan.
    Gambini D; Sala F; Gianotti R; Cusini M
    J Eur Acad Dermatol Venereol; 2003 Jul; 17(4):472-3. PubMed ID: 12834468
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension.
    Debernardi-Venon W; Barletti C; Alessandria C; Marzano A; Baronio M; Todros L; Saracco G; Repici A; Rizzetto M
    Dig Dis Sci; 2002 Feb; 47(2):401-4. PubMed ID: 11855558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical overview of irbesartan: a new angiotensin II receptor antagonist.
    Pouleur HG
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):318S-324S. PubMed ID: 9438776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators.
    Kassler-Taub K; Littlejohn T; Elliott W; Ruddy T; Adler E
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):445-53. PubMed ID: 9607383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholestatic liver injury after glimepiride therapy.
    Chounta A; Zouridakis S; Ellinas C; Tsiodras S; Zoumpouli C; Kopanakis S; Giamarellou H
    J Hepatol; 2005 Jun; 42(6):944-6. PubMed ID: 15885370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute pancreatitis associated with angiotensin II receptor antagonists.
    Fisher AA; Bassett ML
    Ann Pharmacother; 2002 Dec; 36(12):1883-6. PubMed ID: 12452749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).
    Morii J; Miura S; Shiga Y; Sugihara M; Arimura T; Sako H; Zhang B; Uehara Y; Saku K
    Clin Exp Hypertens; 2012; 34(5):342-9. PubMed ID: 22568596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute pancreatitis associated with irbesartan therapy.
    Famularo G; Minisola G; Nicotra GC; De Simone C
    Pancreas; 2005 Oct; 31(3):294-5. PubMed ID: 16163066
    [No Abstract]   [Full Text] [Related]  

  • 13. Regression of left ventricular hypertrophy in human hypertension with irbesartan.
    Malmqvist K; Kahan T; Edner M; Held C; Hägg A; Lind L; Müller-Brunotte R; Nyström F; Ohman KP; Osbakken MD; Ostergern J
    J Hypertens; 2001 Jun; 19(6):1167-76. PubMed ID: 11403367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency.
    Descombes E; Fellay G
    Ren Fail; 2000 Nov; 22(6):815-21. PubMed ID: 11104169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the proinflammatory cytokines, oxidative stress, apoptosis and TGF-β1/STAT-3 signaling by irbesartan to ameliorate doxorubicin-induced hepatotoxicity.
    Kabel AM; Alzahrani AA; Bawazir NM; Khawtani RO; Arab HH
    J Infect Chemother; 2018 Aug; 24(8):623-631. PubMed ID: 29753615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.
    Chiou KR; Chen CH; Ding PY; Chen YT; Ting CT; Huang JL; Chiang AH; Liu CP; Tseng CJ; Chao CT; Chang MS
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):368-76. PubMed ID: 10862446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flucloxacillin induced delayed cholestatic hepatitis.
    Miros M; Kerlin P; Walker N; Harris O
    Aust N Z J Med; 1990 Jun; 20(3):251-3. PubMed ID: 2372276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acute submassive cholestatic hepatitis after treatment with carbimazole. Presentation of a new case and review of the literature].
    Moreno Sánchez D; Medina Asensio J; Colina Ruiz-Delgado F; Campos Cantero R; Crespo Rincón L; Belda Serna A
    Rev Esp Enferm Apar Dig; 1989 Sep; 76(3):273-6. PubMed ID: 2682839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydralazine-induced cholestatic hepatitis.
    Hassan A; Hammad R; Cucco R; Niranjan S
    Am J Ther; 2009; 16(4):371-3. PubMed ID: 19092641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.